6 known cases. View patent page →
This case was resolved through a confidential settlement agreement. A court order found the asserted claims of US Patent 7364736 to be valid, enforceable, and infringed by Sandoz's denosumab biosimilars. The settlement allows Sandoz to launch its biosimilar products on May 31, 2025, or earlier under certain limited conditions.
This BPCIA action is currently pending, with preliminary expedited discovery proceedings related to 29 asserted patents, including US7364736.
A Consent Order and Judgment was entered by stipulation. For the purposes of this action, the asserted claims of all 21 enumerated patents, including US7364736B2, were deemed valid, enforceable, and infringed by Samsung's denosumab biosimilar products.
Amgen filed this BPCIA action asserting infringement of several patents, including US Patent 7364736, against Amneal LLC and mAbxience S.A.U. for their proposed denosumab biosimilar products.
A case involving US7364736.
This is an ongoing patent litigation case in the New Jersey District Court concerning US patent 7364736B2.